B-cell Chronic Lymphocytic Leukemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA approval · 2018-11-28
FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CAMPATH (alemtuzumab) from Genzyme Corporation.